• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza virus nucleoprotein: structure, RNA binding, oligomerization and antiviral drug target

tetano

Editor, Senior Moderator
Future Microbiol. 2013 Dec;8:1537-45. doi: 10.2217/fmb.13.128.
Influenza virus nucleoprotein: structure, RNA binding, oligomerization and antiviral drug target.
Chenavas S, Cr?pin T, Delmas B, Ruigrok RW, Slama-Schwok A.
Source

Universit? Grenoble Alpes, Unit of Virus Host Cell Interactions, F-38000 Grenoble, France.
Abstract

The nucleoprotein (NP) of influenza virus covers the viral RNA entirely and it is this NP-RNA complex that is the template for transcription and replication by the viral polymerase. Purified NP forms a dynamic equilibrium between monomers and small oligomers, but only the monomers can oligomerize onto RNA. Therefore, drugs that stabilize the monomers or that induce abnormal oligomerization may have an antiviral effect, as would drugs that interfere with RNA binding. Crystal structures have been produced for monomeric and dimeric mutants, and for trimers and tetramers; high-resolution electron microscopy structures have also been calculated for the viral NP-RNA complex. We explain how these structures and the dynamic oligomerization equilibrium of NP can be and have been used for anti-influenza drug development.

PMID:
24266354
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/24266354
 
Back
Top Bottom